416 citations,
September 1997 in “Journal of Investigative Dermatology” People with hair loss have more androgen receptors and enzymes in certain follicles, with men and women showing different patterns.
408 citations,
May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.
237 citations,
December 2001 in “Urology” Blocking the enzyme 5α-reductase can shrink the prostate and help treat enlarged prostate issues.
235 citations,
September 2004 in “The Journal of urology/The journal of urology” Drugs that block DHT production can effectively treat enlarged prostate and improve urinary issues with some sexual side effects.
223 citations,
December 2010 in “The Journal of Sexual Medicine” Some patients taking finasteride or dutasteride may have ongoing sexual problems and depression even after stopping the medication.
215 citations,
November 2006 in “Journal of The American Academy of Dermatology” Dutasteride more effective for hair growth, but has more side effects than finasteride.
211 citations,
November 1990 in “The Journal of Steroid Biochemistry and Molecular Biology” Finasteride effectively treats BPH, but needs more trials to understand potential.
195 citations,
February 2007 in “The Journal of Clinical Endocrinology and Metabolism” Dutasteride and finasteride may reduce sperm count and volume but don't affect movement or shape; effects are reversible after stopping.
193 citations,
August 1985 in “Endocrinology” Different animals have unique versions of the enzyme that changes testosterone into another hormone, which is important for creating effective treatments for prostate and hair loss conditions.
184 citations,
January 2000 in “European Urology” Blocking the enzyme that turns testosterone into DHT can safely and effectively treat enlarged prostate.
147 citations,
June 2011 in “New England journal of medicine/The New England journal of medicine” 5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.
147 citations,
April 1990 in “The Journal of Clinical Endocrinology and Metabolism” Finasteride safely lowers DHT levels without affecting testosterone.
124 citations,
March 2012 in “JAMA” Testosterone's muscle-building effects do not require its conversion to DHT.
124 citations,
January 1993 in “The Prostate” Finasteride effectively inhibits 5α reductase, while plant extracts like Permixon and Bazoton don't show significant results.
124 citations,
September 1992 in “Endocrinology” The human type II 5α-reductase gene, linked to certain male health conditions, has a specific structure and low similarity to other related genes.
122 citations,
July 1990 in “Teratology” Finasteride exposure in pregnancy causes genital abnormalities in male rats.
115 citations,
March 2001 in “Baillière's best practice and research in clinical endocrinology and metabolism/Baillière's best practice & research. Clinical endocrinology & metabolism” Key enzymes control androgen levels, affecting hormone activity and potential treatments.
110 citations,
August 2015 in “Neuropsychopharmacology” High-dose dutasteride reduces PMDD symptoms by stabilizing neurosteroid levels.
108 citations,
February 2008 in “The Journal of urology/The journal of urology” Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.
101 citations,
April 1994 in “Baillière's clinical endocrinology and metabolism” 5α-reductase is essential for male sexual development and its inhibitors have potential in treating various conditions related to hormone action.
100 citations,
September 1999 in “British Journal of Dermatology” The study found that two enzymes linked to hair loss are located in different parts of the scalp, supporting a common treatment's effectiveness.
98 citations,
April 1997 in “The Journal of Steroid Biochemistry and Molecular Biology” Finasteride effectively blocks rat enzymes, but with varying methods and strength.
93 citations,
February 2009 in “Annals of the New York Academy of Sciences” 5α‐reductase isozymes are crucial for prostate development and health, and targeting them can help prevent and treat prostate issues.
90 citations,
March 2017 in “JAMA Internal Medicine” Men over 66 taking medication for prostate enlargement have a higher risk of depression and self-harm, especially in the first 18 months of treatment.
89 citations,
February 1993 in “Journal of Medicinal Chemistry” New compounds called benzoquinolinones may treat conditions linked to excess DHT.
86 citations,
March 1993 in “Toxicology and Applied Pharmacology” Finasteride affects male rat genitalia development, causing abnormalities during specific pregnancy days.
82 citations,
February 1989 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.
81 citations,
July 2008 in “The Journal of Clinical Endocrinology and Metabolism” Certain mutations in the H6PD gene cause Cortisone Reductase Deficiency by affecting hormone production.
78 citations,
January 2000 in “Gynecological Endocrinology” Norgestimate is the most effective birth control progestin for reducing an enzyme linked to acne and excessive hair growth in women.
76 citations,
September 1992 in “Endocrinology” The human type II 5α-reductase gene has a specific structure important for understanding certain medical conditions.